

# Content of N1 Bulletin, 2013

## REGULATORY NEWS

- France to suspend sale of DIANE 35. Robert Lowes
- FDA require to lower current recommended doses of zolpidem-containing drugs
- EMA committee gives green light to alcohol abuse drug. Caroline Cassels
- Calcitonin medicines: benefit-risk balance analysis

## THE INTERESTING FACTS

- Metformin boosts survival in ovarian cancer
- UTI treatment in men: shorter may be better. Larry Hand
- Fitness boosts effects of statins. Lisa Nainggolan

## DRUGS SAFETY

- Topical phenylephrine: pulmonary edema.
- Topical tacrolimus: cancers
- Everolimus and serious gastrointestinal disorders
- Everolimus 10 mg and pancreatic neuroendocrine tumors. Many adverse effects and uncertain benefit
- Nicorandil: more cases of mucocutaneous ulceration prolonging marketing authorization is unacceptable.
- Electrocautery and alcohol: risk of fire and burns allow alcohol-based antiseptics to dry.
- Tianeptine: hepatic, neurological and cutaneous adverse effects prolonging marketing authorization is unacceptable.
- Serious skin reactions prompt EMA review of benzodiazepine. Caroline Cassels.
- Orodispersible paracetamol tablets: danger of poisoning in children.
- Single-dose packaging: common errors
- Zinc oxide: artefacts on mammograms. Don't apply ointment before mammography.

## EVIDENCE BASED MEDICINES

- Preventing recurrence after deep vein thrombosis
- Tolperisone. Benefit-risk profile for oral tolperisone considered positive only for adults with post-stroke spasticity and negative for injectable tolperisone.

## FOR GENERAL PHYSICIANS

- Contacts of infectious tuberculosis patients. Monitor those at highest risk of developing tuberculosis
- Doripenem. Higher dosing may be needed in nosocomial pneumonia

## MEDICAL NEWS

- Glue capable of knitting bones
- Daylight effects during pregnancy improve child's vision
- Vaccinated children are more susceptible to some illnesses
- Study: combination of different vaccines kill children

## OUR PUBLICATIONS

- Summary of results of statistical analysis of limited of data of clinical trials of "Armenicum" in variety of indications. Ohanyan T.G. et al.